
Data from Exploratory Analysis Show Merck’s KEYTRUDA® (pembrolizumab) Improved Overall Survival as Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KRAS Mutational Status
Dateline City: KENILWORTH, N.J. New Findings from Phase 3 KEYNOTE-042 Study Were Presented Today at…















.jpg)




.jpg)
